Ubiquigent, a company specialising in providing ubiquitin cell-signalling system drug discovery services and research tools, has enhanced its drug discovery service capabilities by strengthening its commercial and chemistry teams.
Jason Mundin has joined the board as Commercial Director to drive growth along with Jason Brown, founder and now Scientific Director, and Mark Treherne, Executive Chairman.
Laurence Ede also joins the firm as a non-executive director to support the development of the company. John Harris has joined the Scientific Advisory Board to lead Ubiquigent’s new chemistry strategy.
Ede is the former Managing Director and co-owner of Tocris Bioscience, where he gained significant experience within the life science industry. Following a management buyout in late 2006, he focused on developing Tocris to be an increasingly significant player within the life science arena, which in turn led to the successful trade sale of the business to US buyer R&D Systems (Techne) in April 2011.
Mundin began his career as a research scientist at GlaxoSmithKline (GSK), before joining the team that founded Pharmagene Laboratories, which focused on drug discovery through the application of human tissue-based approaches. While at Pharmagene, he transitioned to a commercial role, taking responsibility for business development activities in the UK, US and Japan.
After this Mundin held a number of commercial positions within small and medium-sized biotech companies and latterly headed strategic alliances for the European Bioinformatics Institute, an outstation of the European Molecular Biology Laboratory (EMBL).
Ubiquigent also launched a new website to provide improved access to the drug discovery services, research tools, chemistry and expertise to support ubiquitin system-focused drug discovery and basic research programmes.
